Sign In
Buy BCLI
$0.770
-0.0217 (-2.74%)
At Close: Jun 03, 2026
Non-Small Cell Lung Cancer (NSCLC) Market Insights and Epidemiology 2017-2030 - ResearchAndMarkets.com
12:00am, Monday, 11'th May 2020
The
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q1 2020 Results - Earnings Call Transcript
07:46pm, Sunday, 10'th May 2020
BrainStorm Cell Therapeutics Inc. BCLI) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Sean Leous - ICR Westwicke Chaim Lebovits -
BCLI: The Countdown to Phase 3 ALS Data Begins…
09:35am, Friday, 08'th May 2020
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3 ALS Topline Data in 4Q20 BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 c
Brainstorm Cell Q1 EPS $(0.320) Misses $(0.220) Estimate
10:42am, Thursday, 07'th May 2020BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update
10:30am, Thursday, 07'th May 2020
Conference Call and Webcast Today at 8:30 a.m. Eastern Time ALS Phase 3 Clinical Trial Remains on Track for Q4’20 Top-line Data Readout NEW YORK, May 07, 2020 -- BrainStorm.
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union
09:33am, Thursday, 07'th May 2020BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union
05:00am, Thursday, 07'th May 2020
NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative.
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology
07:30am, Monday, 04'th May 2020
NEW YORK, May 04, 2020 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced.
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology
12:00am, Monday, 04'th May 2020The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update
10:00am, Wednesday, 29'th Apr 2020
NEW YORK, April 29, 2020 -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating.
Acceleron Pharma (NASDAQ:XLRN) vs. Brainstorm Cell Therapeutics (NASDAQ:BCLI) Financial Comparison
01:36pm, Monday, 13'th Apr 2020
Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Acceleron Pharma (NASDAQ:XLRN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of
Analysts Anticipate Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) to Post -$0.22 EPS
10:08am, Saturday, 11'th Apr 2020
Brokerages expect that Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) will post ($0.22) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Br
